Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Sponsor

The First Affiliated Hospital of Zhengzhou University (Other)

Overall Status

Recruiting

CT.gov ID

NCT04216550

Collaborator

(none)

600

Enrollment

Location

Anticipated Duration (Months)

6.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Glioma	Drug: Apatinib

Detailed Description

Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

600 participants

Observational Model:

Cohort

Time Perspective:

Other

Official Title:

MR and Histopathology Images Based Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas Using Artificial Intelligence

Actual Study Start Date :

Jan 1, 2018

Anticipated Primary Completion Date :

Jan 1, 2025

Anticipated Study Completion Date :

Jun 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Apatinib Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death	Drug: Apatinib Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Arm

Intervention/Treatment

Apatinib

Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Drug: Apatinib

Apatinib 0.5g orally daily until the untolerable toxicities, disease progression or death

Outcome Measures

Primary Outcome Measures

Changes of Response to Treatment [From enrollment to progression of disease. Estimated about 6 months]
Response were evaluated with Response Assessment in Neuro-Oncology (RANO) criteria every 1 month after treament.

Secondary Outcome Measures

Progression-Free Survival (PFS) [From enrollment to progression of disease. Estimated about 6 months.]
The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)
Overall Survival (OS) [From enrollment to death of patients. Estimated about 1 year.]
The length of time from enrollment until the time of death (OS, overall survival)
Incidence of treatment-related adverse events [Time Frame: 0 to 1 year]
The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult patients with histologically-confirmed WHO Grade II-IV gliomas which have recurrent or progressive conditions.
With measurable or evaluable disease defined by RANO criteria by MRI scan.
Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2
Life expectancy ≥3 months.
No evidence of serious cardiopulmonary function damage, postoperative complication and hemorrhage on the baseline.
No history of serious hypertension disease.
Patients have adequate organ function as defined by the following criteria:

Hemoglobin (HGB) ≥90g/L
Absolute neutrophil count (ANC) ≥1.5×109/L
White blood cell (WBC) ≥3.0×109/L
Platelet count ≥80×109/L
Alanine aminotransferase(ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis
Creatinine (Cr) of ≤1.25 UNL or creatinine clearance(Ccr) > 45 ml/min.

With written informed consent signed voluntarily by patients themselves.

Exclusion Criteria:

Patients with age<18 or >90 years.
Pregnant or lactating women.
Inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 mmHg on antihypertensive medications).
New York Heart Association (NYHA) Grade II or greater congestive heart failure.
Factors that could have an effect on oral medication.
Abnormal Coagulation (international normalized ratio>1.5, prothrombin time>UNL+4s,activated partial thromboplastin time>1.5 UNL), with tendency of bleeding.
Currently receive thrombolytic and anticoagulation therapy
History of pneumorrhagia(CTCAE grade ≥2 ) or other parts hemorrhage(CTCAE grade ≥3 ) within 4 weeks prior to treatment.
History of artery thrombosis and phlebothrombosis, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, within 6 month prior to treatment.
Medical history of clinically significant thrombosis (bleeding or clotting disorder), excluding warfarin(1mg po qd) and aspirin(80-100mg po qd) for prevention under INR≤1.5.